Transient Immune Modulation for Enzyme Replacement Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current enzyme replacement therapy (ERT) for Pompe disease is often hindered by immune responses, particularly in CRIM-negative patients, leading to high and sustained antibody titers that reduce treatment efficacy and clinical outcomes.
Innovation Solution
A transient low-dose immune modulation regimen using methotrexate, administered concurrently with ERT, to induce immune tolerance and prevent the formation of high and sustained anti-rhGAA immunoglobulin G antibody titers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If enzyme replacement therapy (ERT) is administered to CRIM-negative patients, then the therapeutic enzyme is delivered to target cells, but the patient's immune system recognizes the enzyme as foreign and forms high and sustained anti-rhGAA IgG antibodies that reduce treatment efficacy
Solution Approach 1:
The patent applies preliminary action by administering immune modulators (such as rituximab, methotrexate, or IVIG) before initiating enzyme replacement therapy to CRIM-negative patients. This preemptive immunomodulation conditions the immune system in advance to tolerate the therapeutic enzyme, preventing the formation of high and sustained anti-rhGAA antibodies that would otherwise reduce treatment efficacy. The immune modulators are given for a limited period (e.g., 3-6 months) before ERT begins, creating an immunologically favorable environment for subsequent enzyme administration.
2Object-generated harmful factors
If prolonged immunosuppression is used to minimize antibody titers in patients with established HSAT, then antibody levels are reduced, but the treatment requires prolonged immunosuppression with maintenance doses of rituximab and methotrexate along with bortezomib
Solution Approach 1:
The patent applies preliminary action by administering immune modulators (such as rituximab, methotrexate, or IVIG) before initiating enzyme replacement therapy to CRIM-negative patients. This preemptive immunomodulation conditions the immune system in advance to tolerate the therapeutic enzyme, preventing the formation of high and sustained anti-rhGAA antibodies that would otherwise reduce treatment efficacy. The immune modulators are given for a limited period (e.g., 3-6 months) before ERT begins, creating an immunologically favorable environment for subsequent enzyme administration.
Solution Approach 2:
The patent applies periodic action by using transient, time-limited courses of immune modulators rather than continuous prolonged immunosuppression. The immune modulating agents are administered for specific predetermined periods (e.g., rituximab for 4 weeks, methotrexate for 3-6 months, or IVIG for 5-10 days) and then discontinued. This periodic administration achieves the goal of minimizing antibody titers while avoiding the need for indefinite maintenance dosing, thereby reducing the overall duration and burden of immunosuppressive therapy.
3Object-generated harmful factors
If multiple immune modulating treatment regimens are administered to patients with entrenched immune response, then therapy attempts to decrease existing anti-rhGAA antibodies, but antibody titers persist after multiple treatment regimens
Solution Approach 1:
The patent applies preliminary action by administering immune modulators (such as rituximab, methotrexate, or IVIG) before initiating enzyme replacement therapy to CRIM-negative patients. This preemptive immunomodulation conditions the immune system in advance to tolerate the therapeutic enzyme, preventing the formation of high and sustained anti-rhGAA antibodies that would otherwise reduce treatment efficacy. The immune modulators are given for a limited period (e.g., 3-6 months) before ERT begins, creating an immunologically favorable environment for subsequent enzyme administration.
Solution Approach 2:
The patent applies parameter changes by selecting and combining different immune modulating agents with distinct mechanisms of action (rituximab targeting B-cells, methotrexate affecting T-cell and B-cell function, IVIG providing immunomodulatory antibodies) and adjusting their dosing parameters (duration, timing relative to ERT initiation). This multi-parameter approach addresses entrenched immune responses by changing the immunological parameters before ERT begins, rather than attempting to modify established high-titer antibody responses with single-agent therapies.
Data Source
AI summary
The present disclosure provides compositions and methods for inducing immune tolerance in subjects suffering from metabolic diseases.